These data point to the necessity of also focusing on host genetics, possibly taking into account genotypes of rs1883112 in the NCF4 gene and rs1800871 in the IL10 gene, for a more comprehensive assessment of the outcomes of DLBCL patients in future prospective clinical pharmacogenetic trials. Here, NCF4 is linked to diffuse large B-cell lymphoma.